AGPAT4

Across TCGA pan-cancer cohorts, AGPAT4 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated AGPAT4 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher AGPAT4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AGPAT4 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BLCA, MESO, and COAD are the cancer types where AGPAT4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.141	0.687	.003	21	view →
MESO	OS	Median	All	0.130	0.557	.019	18	view →
COAD	OS	Median	III,IV	0.082	0.792	<.001	12	view →
OV	OS	Median	II,III,IV	0.324	0.691	.049	6	view →
PRAD	DFS	Median	All	0.422	0.888	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.969	0.730	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

AGPAT4–BLCA (OS)

Open the BLCA breakdown →